Trial Profile
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Crizanlizumab (Primary)
- Indications Vaso-occlusive crisis
- Focus Adverse reactions; Pharmacokinetics
- Acronyms SOLACE-kids
- Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals
- 31 Jan 2024 Planned End Date changed from 11 Feb 2026 to 12 Jun 2026.
- 31 Jan 2024 Planned primary completion date changed from 31 May 2024 to 2 Jan 2025.
- 12 Dec 2023 Results of pooled analysis from studies (NCT0189536, NCT03264989, NCT03474965 and NCT03814746 )in patients with SCD, presented at 65th Annual Meeting and Exposition of the American Society of Hematology.